1,479
Views
6
CrossRef citations to date
0
Altmetric
Research Articles

Improving cellular uptake and bioavailability of periplocymarin-linoleic acid prodrug by combining PEGylated liposome

, , , , , & show all
Pages 2491-2497 | Received 13 Jun 2022, Accepted 11 Jul 2022, Published online: 31 Jul 2022

References

  • Fang T, Dong Y, Zhang X, et al. (2016). Integrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumors. Int J Pharm 512:39–48.
  • Gao L, Zhang L, He F, et al. (2021). Surfactant assisted rapid-release liposomal strategies enhance the antitumor efficiency of bufalin derivative and reduce cardiotoxicity. Int J Nanomedicine 16:3581–98.
  • Gu X, Gao Y, Wang P, et al. (2021). Nano-delivery systems focused on tumor microenvironment regulation and biomimetic strategies for treatment of breast cancer metastasis. J Control Release 333:374–90.
  • Guo J, Yu Z, Das M, et al. (2020). Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano 14:5075–89.
  • Huang P, Wang D, Su Y, et al. (2014). Combination of small molecule prodrug and nanodrug delivery: amphiphilic drug–drug conjugate for cancer therapy. J Am Chem Soc 136:11748–56.
  • Large DE, Abdelmessih RG, Fink EA, et al. (2021). Liposome composition in drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv Rev 176:113851.
  • Li G, Sun B, Li Y, et al. (2021). Small-molecule prodrug nanoassemblies: an emerging nanoplatform for anticancer drug delivery. Small 17:2101460.
  • Liu F, Tong D, Li H, et al. (2016). Bufalin enhances antitumor effect of paclitaxel on cervical tumorigenesis via inhibiting the integrin α2/β5/FAK signaling pathway. Oncotarget 7:8896–907.
  • Luo C, Sun J, Sun B, et al. (2016). Facile fabrication of tumor redox-sensitive nanoassemblies of small-molecule oleate prodrug as potent chemotherapeutic nanomedicine. Small 12:6353–62.
  • Ren G, Liu D, Guo W, et al. (2016). Docetaxel prodrug liposomes for tumor therapy: characterization, in vitro and in vivo evaluation. Drug Deliv 23:1272–81.
  • Shen Z, Fisher A, Liu WK, et al. 2018. PEGylated “stealth” nanoparticles and liposomes. In: Parambath, A., Ed, Engineering of Biomaterials for Drug Delivery Systems. Sawtson, UK: Woodhead Publishing, pp, 1–26.
  • Sun B, Luo C, Yu H, et al. (2018). Disulfide bond-driven oxidation-and reduction-responsive prodrug nanoassemblies for cancer therapy. Nano Lett 18:3643–50.
  • Wang B, Lv L, Wang Z, et al. (2014). Nanoparticles functionalized with Pep-1 as potential glioma targeting delivery system via interleukin 13 receptor α2-mediated endocytosis. Biomaterials 35:5897–907.
  • Wang G, Wu B, Li Q, et al. (2020). Active transportation of liposome enhances tumor accumulation, penetration, and therapeutic efficacy. Small 16:2004172.
  • Wang Y, Wang S, Firempong CK, et al. (2017). Enhanced solubility and bioavailability of naringenin via liposomal nanoformulation: preparation and in vitro and in vivo evaluations. AAPS PharmSciTech 18:586–9.
  • Wang Y, Xie H, Ying K, et al. (2021). Tuning the efficacy of esterase-activatable prodrug nanoparticles for the treatment of colorectal malignancies. Biomaterials 270:120705.
  • Xie B, Wan J, Chen X, et al. (2020). Preclinical evaluation of a cabazitaxel prodrug using nanoparticle delivery for the treatment of taxane-resistant malignancies. Mol Cancer Ther 19:822–34.
  • Zahednezhad F, Saadat M, Valizadeh H, et al. (2019). Liposome and immune system interplay: Challenges and potentials. J Control Release 305:194–209.
  • Zhang H-Y, Xu W-Q, Zheng Y-y, et al. (2016). Octreotide-periplocymarin conjugate prodrug for improving targetability and anti-tumor ­efficiency: synthesis, in vitro and in vivo evaluation. Oncotarget 7:86326–38.
  • Zhang H, Wang J, Mao W, et al. (2013). Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. J Control Release 166:147–58.
  • Zhang H, Xu W, Omari-Siaw E, et al. (2017). Redox-responsive PEGylated self-assembled prodrug-nanoparticles formed by single disulfide bond bridge periplocymarin-vitamin E conjugate for liver cancer chemotherapy. Drug Deliv 24:1170–8.
  • Zhang H, Zhu Y, Sun C, et al. (2020). GSH responsive nanomedicines self-assembled from small molecule prodrug alleviate the toxicity of cardiac glycosides as potent cancer drugs. Int J Pharm 575:118980.
  • Zhang T, Li M, Yang R, et al. (2018). Therapeutic efficacy of lipid emulsions of docetaxel-linoleic acid conjugate in breast cancer. Int. J Pharmaceut 546:61–9.